Skip to content

Advertisement

BMC Neuroscience

Research article
Open Access

Expression of iron-related genes in human brain and brain tumors

  • Milla M Hänninen1,
  • Joonas Haapasalo2,
  • Hannu Haapasalo2,
  • Robert E Fleming3, 4,
  • Robert S Britton5,
  • Bruce R Bacon5 and
  • Seppo Parkkila1Email author
BMC Neuroscience200910:36

https://doi.org/10.1186/1471-2202-10-36

©  Hänninen et al; licensee BioMed Central Ltd. 2009

Received: 05 September 2008

Accepted: 22 April 2009

Published: 22 April 2009

Abstract

Background

Defective iron homeostasis may be involved in the development of some diseases within the central nervous system. Although the expression of genes involved in normal iron balance has been intensively studied in other tissues, little is known about their expression in the brain. We investigated the mRNA levels of hepcidin (HAMP), HFE, neogenin (NEO1), transferrin receptor 1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin (HFE2) in normal human brain, brain tumors, and astrocytoma cell lines. The specimens included 5 normal brain tissue samples, 4 meningiomas, one medulloblastoma, 3 oligodendrocytic gliomas, 2 oligoastrocytic gliomas, 8 astrocytic gliomas, and 3 astrocytoma cell lines.

Results

Except for hemojuvelin, all genes studied had detectable levels of mRNA. In most tumor types, the pattern of gene expression was diverse. Notable findings include high expression of transferrin receptor 1 in the hippocampus and medulla oblongata compared to other brain regions, low expression of HFE in normal brain with elevated HFE expression in meningiomas, and absence of hepcidin mRNA in astrocytoma cell lines despite expression in normal brain and tumor specimens.

Conclusion

These results indicate that several iron-related genes are expressed in normal brain, and that their expression may be dysregulated in brain tumors.

Keywords

Brain TumorAmyotrophic Lateral SclerosisMeningiomaMedulla OblongataTransferrin Receptor

Background

Regulation of iron homeostasis is crucial to maintain normal cell function, and abnormal cellular iron content has been associated with various diseases. Iron is an essential cofactor for many proteins particularly in oxidative reactions and, therefore, neuronal tissues with a high rate of oxidative metabolism have a considerable requirement for iron [1]. The central nervous system (CNS) is not directly in contact with the plasma iron pool, because it resides behind the blood-brain barrier. Like many molecules, the entry of iron is tightly regulated by the blood-brain barrier, and specific transport mechanisms are required to transfer iron into the brain tissue [2]. Several gene products involved in the regulation of iron homeostasis are expressed in the murine CNS, including transferrin receptor 1 (TfR1) [3], iron regulatory protein [4], ferritin [3], neogenin [5], and hepcidin [6]. Even though iron has an essential role for normal physiology, it poses a threat to cells and tissues when present in excess. This feature is based on iron's ability to readily participate in oxidation-reduction reactions and the formation of reactive oxygen intermediates [1]. Iron accumulation has been reported in the nervous tissue of patients suffering from various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and age-related macular degeneration [7–10].

Malignant CNS tumors arise worldwide in approximately 189,000 patients per year with an estimated annual mortality of 142,000 [11]. Malignant gliomas, including the most common subtype, glioblastoma, are among the most devastating neoplasms and still pose a great challenge for both diagnosis and treatment. Malignant gliomas derive from glial cells and exhibit aggressive tumor characteristics such as high proliferation rate, diminished apoptosis, and escape from external growth control. A distinctive feature of gliomas is that they very rarely metastasize beyond the CNS, despite their highly invasive and angiogenic capabilities [12].

In neoplastic tissues, the oxygen requirement is high, and thus angiogenesis is often crucial for cancer survival. For malignant CNS tumors, especially gliomas, neovascularization is directly correlated with their biological aggressiveness, degree of malignancy and clinical recurrence, and is inversely correlated with post-operative survival time [13]. Neovascularization is driven by a complex regulatory pathway involving von Hippel-Lindau protein (pVHL) and hypoxia-inducible factor (HIF). In normoxia, the transcription factor HIF is targeted for proteosomal degradation, whereas it is stabilized in hypoxic conditions. HIF accumulation induces the expression of several proangiogenic proteins, including transferrin and TfR1, that are linked to the regulation of cellular iron homeostasis [13].

Hepcidin is a key regulator of iron homeostasis that is abundantly expressed in the liver [14, 15]. Iron overload leads to increased hepcidin synthesis, while anaemia, hypoxia, and inflammation downregulate its expression [16]. A recent study showed that hypoxia downregulates hepcidin expression via the VHL/HIF pathway [17]. Hepcidin acts by modulating the activity of ferroportin, the only iron export protein known to exist in mammalian cells. By binding to ferroportin, hepcidin causes its internalization and degradation and, thereby, decreases cellular iron export [18]. Hemojuvelin and its putative co-regulator, neogenin, are other factors that may be involved in the regulation of hepcidin expression [19–21].

Because malignant cells have a high metabolic rate and require significant quantities of iron for various cellular processes, our hypothesis was that iron related genes are differentially expressed in brain tumor cells versus normal brain tissue. The goal of this study was to investigate the expression levels of genes related to iron homeostasis in both brain tumors and normal brain regions. The mRNA expression levels of hepcidin (HAMP), HFE, neogenin (NEO1), transferrin receptor 1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin (HFE2) were measured. We found that all the studied genes, except for hemojuvelin, were expressed in normal brain, and altered expression patterns were found in brain tumors and astrocytoma cell lines. The results suggest that these genes might play a role in the maintenance of iron homeostasis in the brain, and their differential expression in brain tumors may contribute to tumor pathogenesis.

Methods

Study materials for RNA isolation

The study material consisted of: 1) 18 brain tumors obtained as histopathology samples from surgical patients in Tampere University Hospital, Tampere, Finland between 1983 and 2001 (Table 1); 2) 5 samples of normal brain tissue, and 3) 3 astrocytoma cell lines. The experiments were approved by the Ethical Committee of the Tampere University Hospital and conducted according to the guidelines of the Helsinki Declaration. The brain tumors comprised 4 meningiomas (2 grade II; 2 grade III), 3 oligodendrocytic gliomas (2 grade II; 1 grade III), 2 oligoastrocytic gliomas (1 grade II; 1 grade III), one medulloblastoma (grade IV), one pilocytic astrocytoma (grade I), and 7 diffusively infiltrating astrocytic gliomas (2 grade II; 4 grade III; 1 grade IV). The age of the patients ranged from 19 to 86 years (48 ± 18, mean ± SD). Normal brain tissue was obtained post-mortem upon autopsy, and included samples of cortex, cerebellum, thalamus, medulla oblongata, and hippocampus. The cell lines, CCF-STTG1, U373 MG, and U-87 MG, were originally derived from grade IV astrocytomas (glioblastomas). These cell lines were obtained from the European Collection of Cell Cultures (Salisbury, UK) and were cultured according to the provider's instructions.
Table 1

Patient information for brain tumor samples

Patient

Type of tumor

Stage

Age at diagnosis

Sex

1

Meningioma

I

72

F

2

Meningioma

I

62

F

3

Meningioma

II

86

F

4

Meningioma

II

27

M

5

Oligodendroglioma

II

54

F

6

Oligodendroglioma

II

47

M

7

Oligodendroglioma

III

59

M

8

Oligoastrocytoma

II

44

F

9

Oligoastrocytoma

III

40

M

10

Medulloblastoma

IV

19

F

11

Astrocytoma

I

21

M

12

Astrocytoma

II

26

M

13

Astrocytoma

II

44

F

14

Astrocytoma

III

44

M

15

Astrocytoma

III

51

F

16

Astrocytoma

III

61

F

17

Astrocytoma

III

44

M

18

Astrocytoma

IV

62

M

Statistical analysis

Spearman's rank correlation coefficient was used to determine the influence of age on expression levels. The results were considered statistically significant when the correlation coefficient was < -0.300 or > 0.300, with p-value < 0.05. Mann-Whitney U test was used to evaluate the effect of sex on the expression levels. The results were considered statistically significant when p-value was < 0.05.

RNA isolation and first-strand cDNA synthesis

All tissue specimens to be used for RNA isolation were placed in RNAlater (Ambion, Austin, TX) and stored at -80°C until use. Total RNA was isolated from tissue samples using QIAzol lysis reagent and RNeasy Lipid Tissue Mini Kit (Qiagen, Germantown, MD) and from cell cultures using RNeasy Mini Kit (Qiagen) following the manufacturer's instructions. Both protocols included treatment with RNase-free DNase I (Novagen, Madison, WI). RNA concentration and purity were determined by optical density measurement at 260 and 280 nm. All the samples had an OD260/OD280 ratio of 2.0 or higher. For each sample, 0.6 μg of total RNA were converted into first-strand cDNA using the First-Strand cDNA Synthesis Kit (Fermentas, Burlington, Canada) and oligo d(T) primers according to the protocol recommended by the manufacturer.

Reverse transcription PCR and quantitative real-time PCR

The relative amounts of human HAMP, HFE, NEO1, TFRC, and TFR2 transcripts in different tissues were first assessed by reverse transcription (RT) PCR and then with quantitative real-time PCR using the LightCycler detection system (Roche, Rotkreuz, Switzerland). HFE2 expression was studied only by RT-PCR which remained completely negative. The RT-PCR and the real-time PCR primers for the target transcripts were designed using the complete cDNA sequences deposited in GenBank (accession numbers: NM_000410 for HFE, NM_021175 for HAMP, NM_003234 for TFRC, NM_003227 for TFR2, NM_002499 for NEO1 and NM_213653 for HFE2). To avoid amplification of contaminating genomic DNA, the two primers from each primer set were placed in different exons. HPRT1 (hypoxanthine phosphoribosyl-transferase I), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), TBP (TATA box binding protein), and UBC (ubiquitin C) were used as internal controls to normalize for potential quality and quantity differences between samples. According to study of Vandesompele et al. four internal control genes are required for accurate normalization of the samples [22]. The internal control transcripts and primer sequences for HPRT1, GAPDH, UBC were chosen based on the results of Vandesompele et al. [22]. Table 2 shows the primer sequences used to measure the internal control transcripts and the target transcripts.
Table 2

Primer sequences for quantitative real-time PCR

Gene

Forward primer (5'-3')

Reverse promer (5'-3')

HPRT1*

TGACACTGGCAAAACAATGCA

GGTCCTTTCACCACAAGCT

GAPDH*

TGCACCACCAACTGCTTAGC

GGCATGGACTGTGGTCATGAG

UBC*

ATTTGGGTCGCGGTTCTTG

TGCCTTGACATTCTCGATGGT

TBP

TGCACAGGAGCCAAGAGTGAA

CACATCACAGCTCCCCACCA

HFE

CAACAAGTGCCTCCTTTGGT

GGGGGTACAGCCAAGGTTAT

HAMP

CCACAACAGACGGGACAAC

CTTGCAGCACATCCCACAC

NEO1

GCTGGAAGGCGAGGAATGA

CGGGTGGTAGAGATGACTG

TFRC

CTTTGGACATGCTCATCTGG

TGTTTTCCAGTCAGAGGGACA

TFR2

TGGAGGACACCATCAGGCAA

AGCTGCTCTCCGACCTTCC

HFE2**

GGAGAATTGGATAGCAGAG

AGCAGCAGGAGAGTGAGA

B2M**

TCCAGCGTACTCCAAAGATTCAGG

ATGCGGCATCTTCAAACCTCC

* Primer sequences first described in [22]

** Primers used for RT-PCR only

PCR reactions were performed using ReddyMix PCR Master Mix (ABgene, UK) according to manufacturer's instructions. B2M (beta-2-microglobulin) was used as positive control for the RT-PCR reactions. The PCR products were visualized by gel electrophoresis in 1.5% agarose gel with 0.1 μL/mL ethidium bromide. Quantitative real-time PCR reactions were carried out in a 20 μL volume containing 0.5 μL of first strand cDNA, 1× of QuantiTect SYBR Green PCR Master Mix (Qiagen, Hilden, Germany), and 0.5 μM of forward and reverse primers. Amplification and detection were carried out as follows. After an initial 15-min activation step at 95°C, 45 cycles consisting of denaturation at 94°C, 15 s; annealing at Tm, 20 s; elongation at 72°C, 20 s, and final cooling step. Melting curve analysis was always performed after the amplification to check PCR specificity. To quantify the concentration of both the internal control transcripts and the transcripts for HAMP, HFE, NEO1, TFRC, and TFR2 in the samples, a standard curve for each transcript was established using 5-fold serial dilutions of known concentrations of purified PCR products generated from the same primer sets. Each cDNA sample was tested in triplicate. Replicate analyses were automatically handled by the software of the real-time PCR machine. The crossing point value obtained was utilized to determine the amount of original transcript using the specific standard curve. The geometric mean of the 4 internal control transcripts was used as a normalization factor for gene expression levels [22]. The final relative mRNA expression was designated as the copy number of a target transcript in each tissue divided by the corresponding normalization factor and subsequently multiplied by 102 or 103.

Results and discussion

In this study, the mRNA expression levels of hepcidin (HAMP), HFE, neogenin (NEO1), TfR1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin (HFE2) were examined in normal human brain tissue, brain tumors, and astrocytoma cell lines. Hemojuvelin showed no expression in RT-PCR experiments and, therefore, it was not analyzed further by quantitative real-time PCR.

The statistical analysis revealed no significant influence of either age or sex on the expression levels of genes studied.

Hepcidin (HAMP) showed relatively high expression levels in all brain regions examined (Fig. 1); the highest expression was found in the cortex and thalamus. Previously, hepcidin expression has been demonstrated in murine brain [6], but it appears to be absent in the catfish brain [23]. Taken together, these results indicate that hepcidin mRNA is produced in mammalian brain tissue where the encoded hepcidin peptide may contribute to iron homeostasis as well as to mechanisms protecting the CNS from microbial infections. Most tumor samples had lower expression of hepcidin compared to normal brain cortex, and the levels were negligible in the astrocytoma cell lines (Fig. 1). The absence of hepcidin mRNA in the astrocytoma cell lines was surprising because it was expressed in most tissue specimens. One explanation could be that some non-neuronal/non-glial cells such as endothelial cells might be the predominant site of hepcidin expression in the brain. However, this is unlikely because Zechel et al. [6] have reported hepcidin expression in both neurons and glia cells. It is important to realize that the cell lines were cultured in optimized and normoxic conditions, while the hypoxia is the key regulator of variable genes in tumors growing in the hostile environment [13, 24]. Although the exact molecular mechanisms remain unclear, intratumoral factors including paracrine regulation might contribute to the unexpected expression pattern of hepcidin. Cultured cells may be lacking some key factors which induce intratumoral hepcidin expression. Previous studies have identified several factors that regulate hepcidin mRNA expression in the liver. For example, iron overload increases hepcidin expression, whereas anemia and hypoxia lead to downregulation [25]. Hypoxia acting through a VHL/HIF-induced pathway induces the expression of several genes in tumors which, in turn, may increase the resistance of tumor cells to their hostile microenvironment [26, 27]. Peyssonnaux et al. [17] recently showed that a VHL/HIF pathway regulates hepatic hepcidin expression in vivo, but the potential role of this pathway in modulating brain hepcidin is unknown.
Figure 1
Figure 1

Hepcidin mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is normalized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cortex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers in astrocytomas indicate tumor grade.

Hemojuvelin also plays an important role in hepcidin regulation in the liver, acting as a co-receptor for bone morphogenetic protein [20]. Hemojuvelin exists in both membrane-bound and soluble forms, and Silvestri et al. [28] have demonstrated regulation of soluble hemojuvelin via HIF-1α and furin. However, our results indicate that hemojuvelin mRNA is not expressed in normal brain tissue or in brain tumors. A previous study demonstrated that murine brain also does not express hemojuvelin [5]. Taken together, the available data suggest that hemojuvelin may not regulate hepcidin expression in the brain, or soluble hemojuvelin produced elsewhere is transferred across the blood-brain barrier to regulate hepcidin expression in the brain.

Neogenin has been demonstrated to interact with hemojuvelin, and it has been hypothesized that, through this interaction, neogenin may influence hepcidin expression [19, 21, 29]. A previous report has shown that neogenin is expressed widely in murine tissues, including the brain [5]. We observed that neogenin mRNA is abundant in normal human brain tissue, and the highest expression levels were found in the medulla oblongata and hippocampus (Fig. 2). In contrast, neogenin mRNA levels were low in oligodendrogliomas, oligoastrocytomas, medulloblastomas, and astrocytomas, while in meningiomas and astrocytoma cell lines, neogenin mRNA expression is within the same range as seen in normal brain regions. This diverse expression pattern in brain tumors is not unexpected because both overexpression and repression of neogenin have been previously reported in neoplastic tissues [30, 31]. The function of neogenin in the adult brain tissue remains to be determined.
Figure 2
Figure 2

Neogenin mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is normalized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cortex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers in astrocytomas indicate tumor grade.

In the brain, the highest expression levels for TfR1 mRNA were in the medulla oblongata and the hippocampus, and expression was distinctly lower in the cortex, thalamus, and cerebellum (Fig. 3). The brain tumors had no differential expression of TfR1 mRNA compared to normal human cortex. However, the astrocytoma cell lines had substantially higher TfR1 expression than the brain tumors. These differences in TfR1 expression levels agree with the expression intensities and patterns observed in a previous study [32]. The cerebellum was the only part of the normal brain expressing TfR2 mRNA (Fig. 4). Some TfR2 mRNA expression was present in a few brain tumor specimens, with possible differential expression in oligoastrocytomas. TfR2 mRNA was not expressed in astrocytoma cell lines.
Figure 3
Figure 3

Transferrin receptor 1 mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is normalized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cortex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers in astrocytomas indicate tumor grade.

Figure 4
Figure 4

Transferrin receptor 2 mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is normalized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cortex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers in astrocytomas indicate tumor grade.

The HFE gene encodes a MHC type 1-like protein that is involved in modulating iron homeostasis [33, 34]. We observed that HFE mRNA was expressed at low levels in human cortex, cerebellum, and thalamus, but not in medulla oblongata or hippocampus (Fig. 5). Brain tumors and astrocytoma cell lines showed somewhat higher expression of HFE mRNA than normal cortex. The highest mRNA levels were present in 3 out of 4 meningioma specimens. Mutations in the HFE gene result in the most common form of hereditary hemochromatosis. Interestingly, some studies suggest that one of the most common HFE mutations, H63D, may be a genetic modifier for increased risk of Alzheimer's disease and amyotrophic lateral sclerosis [35–37].
Figure 5
Figure 5

HFE mRNA expression in normal brain and brain tumors detected by real-time PCR. The expression is normalized using internal control genes and relative expression levels are shown. *Abbreviations used for normal brain: Cx = cortex, Cb = cerebellum, T = thalamus, M = medulla oblongata, H = hippocampus. Tumor samples are numbered according to Table 1. Numbers 19 to 21 are used to indicate cell lines: 19 = CCF-STTG1, 20 = U373MG, 21 = U-87 MG. **Roman numbers in astrocytomas indicate tumor grade.

Although investigation of the molecular basis of iron homeostasis has been intensive after the discovery of the HFE gene in 1996 [34], little is still known about the role of iron and iron-related genes in the brain. In this study, we show that many of the genes considered essential for the regulation of iron homeostasis outside the CNS are also expressed in the brain. Iron regulation in the brain is complex, and in future studies it will be of great interest to investigate the protein expression of these molecules in different brain regions along with assessment of regional iron concentrations. Due to the presence of the blood-brain barrier, the CNS can adjust its iron status somewhat independently of other organs. Our results also indicate that the expression pattern of iron-related genes can vary markedly in tumors arising within the brain. Further investigation will be required to evaluate whether the dysregulated expression of iron-related genes in brain tumors may contribute to tumor pathogenesis.

Conclusion

The present study describes the expression of several iron-related genes including hepcidin (HAMP), HFE, neogenin(NEO1), transferrin receptor 1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin(HFE2) in normal human brain, brain tumors, and astrocytoma cell lines. Our results suggested that all these genes except for HFE2 are expressed in the normal brain, and that their expression may be dysregulated in certain brain tumors.

Declarations

Acknowledgements

We thank Mrs. Aulikki Lehmus and Mrs. Reija Randen for skilful technical assistance and Mrs. Anna-Maija Koivisto for assistance with statistical analysis. This work was supported by grants from the Medical Research Fund of Tampere University Hospital and the Sigrid Juselius Foundation.

Authors’ Affiliations

(1)
Institute of Medical Technology and School of Medicine, University of Tampere, Tampere University Hospital, Tampere, Finland
(2)
Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland
(3)
Department of Pediatrics, Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, USA
(4)
Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, USA
(5)
Division of Gastroenterology and Hepatology, Saint Louis University Liver Center, Saint Louis University School of Medicine, St. Louis, USA

References

  1. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR: Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004, 5 (11): 863-873. 10.1038/nrn1537.View ArticlePubMedGoogle Scholar
  2. Burdo JR, Connor JR: Brain iron uptake and homeostatic mechanisms: an overview. Biometals. 2003, 16 (1): 63-75. 10.1023/A:1020718718550.View ArticlePubMedGoogle Scholar
  3. Moos T: Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. J Comp Neurol. 1996, 375 (4): 675-692. 10.1002/(SICI)1096-9861(19961125)375:4<675::AID-CNE8>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
  4. Leibold EA, Gahring LC, Rogers SW: Immunolocalization of iron regulatory protein expression in the murine central nervous system. Histochem Cell Biol. 2001, 115 (3): 195-203.PubMedGoogle Scholar
  5. Rodriguez A, Pan P, Parkkila S: Expression studies of neogenin and its ligand hemojuvelin in mouse tissues. J Histochem Cytochem. 2007, 55 (1): 85-96. 10.1369/jhc.6A7031.2006.View ArticlePubMedGoogle Scholar
  6. Zechel S, Huber-Wittmer K, von Bohlen O, Halbach O: Distribution of the iron-regulating protein hepcidin in the murine central nervous system. J Neurosci Res. 2006, 84 (4): 790-800. 10.1002/jnr.20991.View ArticlePubMedGoogle Scholar
  7. Wong RW, Richa DC, Hahn P, Green WR, Dunaief JL: Iron toxicity as a potential factor in AMD. Retina. 2007, 27 (8): 997-1003. 10.1097/IAE.0b013e318074c290.View ArticlePubMedGoogle Scholar
  8. Miwa H, Okawa M, Kajimoto Y, Kondo T: Transcranial sonography of the substantia nigra in patients with Parkinson's disease. J Neurol. 2007, 254 (Suppl 4): IV15-IV20. 10.1007/s00415-007-4004-z.Google Scholar
  9. Carri MT, Ferri A, Cozzolino M, Calabrese L, Rotilio G: Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull. 2003, 61 (4): 365-374. 10.1016/S0361-9230(03)00179-5.View ArticlePubMedGoogle Scholar
  10. Collingwood J, Dobson J: Mapping and characterization of iron compounds in Alzheimer's tissue. J Alzheimers Dis. 2006, 10 (2–3): 215-222.PubMedGoogle Scholar
  11. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.View ArticlePubMedGoogle Scholar
  12. Reardon DA, Rich JN, Friedman HS, Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006, 24 (8): 1253-1265. 10.1200/JCO.2005.04.5302.View ArticlePubMedGoogle Scholar
  13. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D: Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005, 15 (4): 297-310.View ArticlePubMedGoogle Scholar
  14. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001, 276 (11): 7806-7810. 10.1074/jbc.M008922200.View ArticlePubMedGoogle Scholar
  15. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003, 102 (3): 783-788. 10.1182/blood-2003-03-0672.View ArticlePubMedGoogle Scholar
  16. Atanasiu V, Manolescu B, Stoian I: Hepcidin – central regulator of iron metabolism. Eur J Haematol. 2007, 78 (1): 1-10. 10.1111/j.1600-0609.2006.00772.x.View ArticlePubMedGoogle Scholar
  17. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS: Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007, 117 (7): 1926-1932. 10.1172/JCI31370.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004, 306 (5704): 2090-2093. 10.1126/science.1104742.View ArticlePubMedGoogle Scholar
  19. Zhang AS, West AP, Wyman AE, Bjorkman PJ, Enns CA: Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells. J Biol Chem. 2005, 280 (40): 33885-33894. 10.1074/jbc.M506207200.View ArticlePubMedGoogle Scholar
  20. Ganz T: Iron homeostasis: fitting the puzzle pieces together. Cell Metab. 2008, 7 (4): 288-290. 10.1016/j.cmet.2008.03.008.View ArticlePubMedGoogle Scholar
  21. Yang F, West AP, Allendorph GP, Choe S, Bjorkman PJ: Neogenin interacts with hemojuvelin through its two membrane-proximal fibronectin type III domains. Biochemistry. 2008, 47 (14): 4237-4245. 10.1021/bi800036h.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3 (7): RESEARCH0034-10.1186/gb-2002-3-7-research0034.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Bao B, Peatman E, Li P, He C, Liu Z: Catfish hepcidin gene is expressed in a wide range of tissues and exhibits tissue-specific upregulation after bacterial infection. Dev Comp Immunol. 2005, 29 (11): 939-950. 10.1016/j.dci.2005.03.006.View ArticlePubMedGoogle Scholar
  24. Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer. 2008, 8 (12): 967-975. 10.1038/nrc2540.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002, 110 (7): 1037-1044.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, Kogel van der AJ, Riggins GJ: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst. 2001, 93 (17): 1337-1343. 10.1093/jnci/93.17.1337.View ArticlePubMedGoogle Scholar
  27. Schofield CJ, Ratcliffe PJ: Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004, 5 (5): 343-354. 10.1038/nrm1366.View ArticlePubMedGoogle Scholar
  28. Silvestri L, Pagani A, Camaschella C: Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008, 111 (2): 924-931. 10.1182/blood-2007-07-100677.View ArticlePubMedGoogle Scholar
  29. Zhang AS, Yang F, Meyer K, Hernandez C, Chapman-Arvedson T, Bjorkman PJ, Enns CA: Neogenin-mediated hemojuvelin shedding occurs after hemojuvelin traffics to the plasma membrane. J Biol Chem. 2008, 283 (25): 17494-17502. 10.1074/jbc.M710527200.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Hu YC, Lam KY, Law S, Wong J, Srivastava G: Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res. 2001, 7 (8): 2213-2221.PubMedGoogle Scholar
  31. Lee JE, Kim HJ, Bae JY, Kim SW, Park JS, Shin HJ, Han W, Kang KS, Noh DY: Neogenin expression may be inversely correlated to the tumorigenicity of human breast cancer. BMC Cancer. 2005, 5: 154-10.1186/1471-2407-5-154.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Recht L, Torres CO, Smith TW, Raso V, Griffin TW: Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg. 1990, 72 (6): 941-945.View ArticlePubMedGoogle Scholar
  33. Fleming RE, Britton RS: Iron Imports. VI. HFE and regulation of intestinal iron absorption. Am J Physiol Gastrointest Liver Physiol. 2006, 290 (4): G590-594. 10.1152/ajpgi.00486.2005.View ArticlePubMedGoogle Scholar
  34. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, et al.: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996, 13 (4): 399-408. 10.1038/ng0896-399.View ArticlePubMedGoogle Scholar
  35. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, Morgadinho AS, Ribeiro MH, Hardy J, Singleton A, Oliveira C: Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 2006, 6: 24-10.1186/1471-2377-6-24.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, Connor J: Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci. 2004, 227 (1): 27-33. 10.1016/j.jns.2004.08.003.View ArticlePubMedGoogle Scholar
  37. Connor JR, Lee SY: HFE mutations and Alzheimer's disease. J Alzheimers Dis. 2006, 10 (2–3): 267-276.PubMedGoogle Scholar

Copyright

© Hänninen et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Neuroscience

ISSN: 1471-2202

Contact us